Загрузка компании
Just reported
Q3 2026 results
From Immunome's results release of 9 ноября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
0,00 $
Guided
—
No guide given
EPS, GAAP
Actual
-0,76 $
Guided
—
No guide given
Operating income, GAAP
Actual
-90,4M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Immunome is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
На чём зарабатывает
- Research collaboration payments (historical)
Конкурирует с
- MKKGYMerck KGaA (through SpringWorks Therapeutics)
- MRKMerck & Co.A
- Размер
- 364,3B $
- Маржа
- 3,6 %
- 2616CStone Pharmaceuticals
- NVSNovartisA
- Размер
- 306,3B $
- Маржа
- -0,1 %
- CATXPerspective Therapeutics
- Размер
- 114,3M $
- Ratio Therapeutics
Что продаёт6
Varegacestat
An investigational, once-daily pill being developed to treat desmoid tumors, which can grow into nearby tissue.
IM-1021
An experimental antibody-drug conjugate designed to carry cancer-killing medicine to cells with the ROR1 marker; it is being tested in people with lymphoma and solid tumors.
IM-1617
An experimental antibody-drug conjugate designed to target a receptor found on some solid tumors.
Показать ещё 3
IM-3050
An experimental treatment that uses a molecule aimed at the FAP marker to deliver radioactive lutetium-177 to cells in solid tumors.
IM-1340
An experimental antibody-drug conjugate being developed for solid tumors, including some lung and prostate cancers.
IM-1335
An experimental antibody-drug conjugate being developed to treat solid tumors; its target has not been publicly named.
Кто покупает1
- AbbVie paid for research work under a collaboration agreement that ended in July 2025 (high confidence); Immunome has not reported product-sale customers.
На чём держится и что может это сломать
От чего зависит бизнес
- 1Immunome relies on outside manufacturers for materials used in its named drug programs and expects to rely on them for future commercial supply.
- 2The IM-3050 clinical trial depends on third-party diagnostic radiotracer supply; its treatment also requires radioactive lutetium-177.
- 3Varegacestat is licensed from Bristol Myers Squibb, and Immunome owes that company royalties and potential milestone payments if the drug is developed and sold.
Что может пойти не так
- 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
- 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
- 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.
Полная финансовая отчётность →
О компании Immunome Inc.
Immunome develops medicines intended to treat cancer. Its main drug candidate, varegacestat, is an investigational pill for desmoid tumors; the company has submitted a marketing application in the United States. Its other experimental treatments include drugs designed to deliver cancer-killing medicine or radiation to tumors.
- Штаб-квартира
- Exton, Pennsylvania, United States
- Год основания
- 2006
- Торгуется на
- Nasdaq
- Конец финансового года
- December 31
Построено по собственной отчётности Immunome Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
